Caricamento azienda
Just reported
Q3 2026 results
From Co.-Diagnostics's results release of 10 novembre 2026; its quarterly report has since been filed.
Revenue
Actual
282,9K USD
+95% y/y
+70% q/qGuided
—
No guide given
EPS, GAAP
Actual
-1,01 USD
Guided
—
No guide given
Operating income, GAAP
Actual
-6,3M USD
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Co.-Diagnostics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc130B USDA+
SYKStryker Corp.121,3B USDA+
EWEdwards Lifesciences Corporation60,8B USDA+
GEHCGE Healthcare Technologies Inc.37,4B USDA
GKOSGlaukos Corp14,6B USDA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 ott 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A- EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 ott 2026BAGraded B, now A
Costruito dai documenti depositati da Co.-Diagnostics, Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.
